Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
January 27, 2024 at 13:40 PM EST
ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it aims to bring to the US market.
